AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 133 min read$SMMT

Summit Therapeutics (SMMT) Gains Attention as Phase III Trial Da

Summit Therapeutics (SMMT) reported updated interim results from the Phase III HARMONi-2 trial of ivonescimab, showing a 27% reduction in death risk in non-small cell lung cancer. The company has a high P/S ratio of 14,000x and a GF Score of 31. Insiders bought $114.6M in shares over 12 months. Summit remains unprofitable but has a market cap of $14B.

Original reporting
gurufocus.com
Published Sep 13, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 5:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
9/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$SMMTBullishHigh
01

Why it matters

The interim survival benefit provides a strong catalyst for SMMT, potentially driving share price higher as investors factor in the positive efficacy signal.

02

Market read

The trial data is a material catalyst for Summit Therapeutics and may influence broader biotech sentiment.

03

What to watch

Long timeline to commercialization and competition from other PD‑L1 therapies may limit impact.

Relevance 9/10Novelty 9/10Timing: announced today

Background

Summit Therapeutics (NASDAQ: SMMT) announced updated interim results from its partner Akeso's Phase III HARMONi-2 trial of ivonescimab in NSCLC, showing a hazard ratio of 0.73 and improved overall survival, with data to be presented at a conference in Seoul.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Summit Therapeutics reported positive interim overall survival data from the Phase III HARMONi-2 trial, showing a 27% reduction in risk of death versus pembrolizumab.

Expected impact

Potential upside as the market re‑rates the company's oncology pipeline.

Evidence & confidence

The interim analysis showed a hazard ratio of 0.73, indicating better survival outcomes, which is material for a clinical‑stage biotech.

Market effects

Sector

Positive oncology data could boost sentiment across the biotech sector.

Regional

US biotech stocks may see buying pressure following the news.

Global

Global investors may reassess oncology pipeline valuations after the trial results.

Counterpoint

What could challenge this read

Despite the trial data, Summit's extreme valuation and cash burn raise concerns about upside.

Key entities

  • company
    Summit Therapeutics Inc

    US‑listed biotech developing oncology and antibiotic therapies.

  • partner
    Akeso

    Collaborator conducting the HARMONi-2 trial of ivonescimab.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 14
$SMMTMedAI 8/10

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Condu

Summit Therapeutics' partner Akeso announced that ivonescimab, a bispecific antibody, showed a 27% reduction in death risk and an 8.2-month improvement in median overall survival compared to pembrolizumab in the HARMONi-2 study for PD-L1-positive advanced NSCLC. The trial met its secondary endpoint with a hazard ratio of 0.73. Ivonescimab is approved in China and is being studied in a global Phase III trial (HARMONi-7).

biospace.com2 min
SEP 13
$SMMTHighAI 9/10

Summit Therapeutics (SMMT) Shows Promising Trial Results but Fac

Summit Therapeutics (SMMT) reported that its drug ivonescimab showed a 27% reduction in mortality risk compared to Merck’s Keytruda in a late-stage lung cancer trial. The company's P/S ratio is 37,930x, significantly higher than its historical median of 370x, reflecting high growth expectations. Insiders have bought $114.6 million in shares over the past year, while guru activity is mixed.

gurufocus.com3 min
SEP 9
$SMMTHigh

Summit Therapeutics stock surges on Jefferies upgrade to buy

Summit Therapeutics (SMMT) shares rose 5.8% premarket after Jefferies upgraded it to Buy and raised its price target to $25. The upgrade is ahead of expected H3 progression-free survival data in late 2026, with Jefferies predicting statistical significance and a potential overall survival win by early 2027. The analyst cited the company's mechanism of action and ivonescimab's first-in-class status as key drivers.

investing.com1 min
SEP 9
$SMMTHighAI 9/10

Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab

Summit Therapeutics (SMMT) announced that its partner Akeso reported a statistically significant overall survival benefit for ivonescimab over pembrolizumab in the Phase 3 HARMONi-2 study. The trial involved 398 patients with advanced non-small cell lung cancer. Earlier data showed ivonescimab's median progression-free survival was 11.1 months, compared to 5.8 months for pembrolizumab. The hazard ratio was 0.51, indicating a 49% reduction in progression or death risk. Summit did not disclose the

yahoo.com2 min